Test ID APBCC Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Spinal Fluid
Method Name
Only orderable as a part of a profile or reflex. For more information see:
-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid
Cell-Binding Assay (CBA)
Specimen Required
Only orderable as a part of a profile or reflex. For more information see:
-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid
Reporting Name
AP3B2 CBA, CSFSpecimen Type
CSFSpecimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| CSF | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Report Available
5 to 10 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| APBCC | AP3B2 CBA, CSF | 101907-4 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 615860 | AP3B2 CBA, CSF | 101907-4 |
Useful For
The differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy
Evaluating AP3B2 (adaptor protein 3 beta2)-IgG by cell-binding assay using spinal fluid specimens
Testing Algorithm
If the indirect immunofluorescence (IFA) pattern suggests AP3B2 (adaptor protein 3 beta2), then this test and AP3B2 antibody IFA titer will be performed at an additional charge.
Day(s) Performed
5 days if negative/10 days if positive
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255
Specimen Minimum Volume
See Specimen Required
Reference Values
Only orderable as a part of a profile or reflex. For more information see:
-MAC1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid
Negative